Apixaban in Subjects With Peritoneal Dialysis

Summary

The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.

Timeline

Start

2019-12-08

Primary completion

2022-12-10

Completion

2022-12-10

Publications

• Results Peyro-Saint-Paul L, Bechade C, Cesbron A, Debruyne D, Brionne M, Brucato S, Hanoy M, Dumont A, Briant AR, Parienti JJ, Lobbedez T, Ficheux M. Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics. Nephrol Dial Transplant. 2023 Jul 31;38(8):1918-1920. doi: 10.1093/ndt/gfad087. No abstract available.

Drugs

Indications